Chinese ALS Drug Completes Phase 2 Trials, Eyes Market Next Year

A new domestic Chinese drug for Amyotrophic Lateral Sclerosis (ALS), specifically targeting SOD1 gene mutations, has completed its Phase 2 clinical trials. The development was significantly driven by ALS patient and former JD.com Vice President Cai Lei, who played a key role in connecting research companies and medical experts.

The drug, a collaboration between domestic pharmaceutical firms and researchers at the Institute of Neurology at Beijing's Tiantan Hospital, has shown promising initial results. These findings were recently published in the international scientific journal Nature Medicine. This medication is designed to benefit approximately 10% of ALS patients who carry the SOD1 gene mutation, a condition that leads to the accumulation of toxic proteins and the death of motor neurons.

This domestically developed drug represents a potential advancement over existing treatments in China, which currently consist of two imported medications. Those drugs can only slow the progression of ALS and cannot reverse or halt it. The new drug aims to tackle the disease at its genetic root by "sealing" the SOD1 gene to stop the production of harmful proteins.

Early clinical data from the Phase 2 trials are encouraging. Six patients treated for 240 days showed a substantial reduction in toxic protein levels in their cerebrospinal fluid and a significant decrease in blood markers for nerve damage. Some patients who previously had difficulty moving their toes have reportedly regained some mobility.

While Cai Lei, who himself does not have the SOD1 mutation, will not directly benefit from this particular drug, his advocacy highlights the importance of patient-led research initiatives. The drug is expected to have potential advantages in efficacy duration and cost compared to current options, especially given its domestic origin.